Robert Hauser I-5372-2012

Robert Hauser, MD, MBA

Director, Parkinson's & Movement Disorder Center

Professor, College of Medicine Neurology

Contact Info 4001 E. Fletcher Ave
6th Floor
Tampa FL 33613

Academic Email: rhauser@health.usf.edu

Academic Phone:(813) 396-0751

View My C.V.

Education

  • MBA, Business Administration, University of South Florida, 2000
  • MD, Medicine, Temple University, 1982

Interdisciplinary and Emerging Signature Programs

  • Neuroscience

Memberships

  • American Academy of Neurology (Fellow, 2004 - Present)
  • Movement Disorders Society (Member, 1988 - Present)
  • American Academy of Neurology (Member, 1988 - Present)

Recent Publications

  • Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the neurological sciences. 373: 116-123, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28131167
  • Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Movement disorders : official journal of the Movement Disorder Society. , 2017. http://www.ncbi.nlm.nih.gov/pubmed/28833562
  • Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. Journal of Parkinson's disease. 7(3) : 511-522, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28777755
  • Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Movement disorders : official journal of the Movement Disorder Society. , 2017. http://www.ncbi.nlm.nih.gov/pubmed/28646494
  • Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert opinion on pharmacotherapy. 18(12) : 1279-1287, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28699794
  • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet. Psychiatry. 4(8) : 595-604, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28668671
  • Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA neurology. 74(8) : 941-949, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28604926
  • Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Annals of clinical and translational neurology. 4(6) : 360-368, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28589163
  • Tilley BC, Mainous AG, Smith DW, McKee MD, Amorrortu RP, Alvidrez J, Diaz V, Ford ME, Fernandez ME, Hauser RA, Singer C, Landa V, Trevino A, DeSantis SM, Zhang Y, Daniels E, Tabor D, Vernon SW. Design of a cluster-randomized minority recruitment trial: RECRUIT. Clinical trials (London, England). 14(3) : 286-298, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28545336
  • Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 88(23) : 2198-2206, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28490648
  • Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. Journal of the neurological sciences. 377: 137-143, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28477684
  • Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 88(21) : 2003-2010, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28446646
  • Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 32(5) : 783-789, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28370340
  • Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. The American journal of psychiatry. 174(5) : 476-484, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28320223
  • Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T. Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the neurological sciences. 375: 355-359, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28320167
  • White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. The American journal of cardiology. 119(7) : 1111-1115, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28159196
  • Valdés EG, O'Connor ML, Uc EY, Hauser RA, Andel R, Edwards JD. Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. The International journal of neuroscience. 127(10) : 841-848, 2017. http://www.ncbi.nlm.nih.gov/pubmed/27919204
  • Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. Journal of Parkinson's disease. 7(1) : 117-127, 2017. http://www.ncbi.nlm.nih.gov/pubmed/27911341
  • Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA neurology. 74(2) : 216-224, 2017. http://www.ncbi.nlm.nih.gov/pubmed/27942720
  • Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 31(9) : 1366-72, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27430123
  • Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clinical neuropharmacology. 39(5) : 220-6, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27332626
  • Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. BMC neurology. 16: 90, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27267880
  • LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. , 2016. http://www.ncbi.nlm.nih.gov/pubmed/27090868
  • Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Movement Disorders : Official Journal of the Movement Disorder Society. 31(5) : 709-14, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27030249
  • Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW. Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 31(10) : 1489-1496, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27431201
  • François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data. Journal of Medical Economics. 19(5) : 515-25, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26710315
  • , Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurology. 73(1) : 102-10, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26569098
  • Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK. Communicating with participants during the conduct of multi-center clinical trials. Clinical trials (London, England). 13(6) : 592-596, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27573636
  • François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. BMC neurology. 16(1) : 143, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27538531
  • Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism & related disorders. 33: 127-133, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27743701
  • Hauser RA, Abler V, Eyal E, Eliaz RE. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies. The International Journal of Neuroscience. 126(10) : 942-6, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26988747
  • Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opinion on Pharmacotherapy. 16(18) : 2807-17, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26595228
  • Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurology. 72(12) : 1491-500, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26523919
  • Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clinical Neuropharmacology. 38(5) : 163-9, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26366971
  • O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 30(12) : 1681-7, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26346941
  • Hauser RA. α-Synuclein in Parkinson's disease: getting to the core of the matter. The Lancet. Neurology. 14(8) : 785-6, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26116313
  • Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Movement Disorders : Official Journal of the Movement Disorder Society. 30(5) : 646-54, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25487613
  • Wechsler R, Hauser RA, French J. Who is helping whom? Manuscript support and transfer of value. Annals of Neurology. 77(2) : 353-5, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25583380
  • Poewe W, Hauser RA, Lang A. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Movement Disorders : Official Journal of the Movement Disorder Society. 30(4) : 589-92, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25545629
  • Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Movement Disorders : Official Journal of the Movement Disorder Society. 30(4) : 500-9, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25545465
  • Hauser RA. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evidence-based Medicine. 20(1) : 17, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25525039
  • Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Movement Disorders : Official Journal of the Movement Disorder Society. 30(6) : 788-95, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25650051
  • Kremens D, Hauser RA, Dorsey ER. An update on Parkinson's disease: improving patient outcomes. The American Journal of Medicine. 127(1) : S3, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24384115
  • Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinson's Disease. 2014: 467131, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24800101
  • Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J,. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13(3) : 268-75, 2014.
  • The Parkinson Study Group QE3 Investigators (including Hauser RA). A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 71(5) : 543-52, 2014.
  • Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper J, Hauser R, Mantovani D, Barker R, Freeman T. Mutant huntingtin is present in neuronal grafts in Huntington's disease patients. Ann Neurol. 76(1) : 31-42, 2014.
  • Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. , 2014.
  • Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Pramipexole ER Studies Group.Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 21(5) : 736-43, 2014.
  • Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA,. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 29(9) : 1171-80, 2014.
  • Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S, for the ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease Mov Disord. 29(8) : 1028-34, 2014.
  • Bajaj N, Hauser RA, Seibyl J, Kupsch A, Plotkin M, Chen C, Grachev ID. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes. Alzheimer's Research & Therapy. 6: 67, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25478029
  • Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism & Related Disorders. 20(11) : 1171-6, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25239603
  • Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. The Lancet. Neurology. 13(8) : 767-76, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25008546
  • Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O'Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID. Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55(8) : 1288-96, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24925885
  • Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29(8) : 1028-34, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24919813
  • Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism & Related Disorders. 20(2) : 142-8, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24055014
  • Lewitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24339234
  • HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease JAMA Neurol. 70(1) : 25-33, 2013.
  • Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism & Related Disorders. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24182524
  • Edwards JD, Hauser RA, O'Connor ML, Valdés EG, Zesiewicz TA, Uc EY. Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology. 81(15) : 1284-90, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24014503
  • Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. The International Journal of Neuroscience. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24007304
  • Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement Disorders : Official Journal of the Movement Disorder Society. 28(13) : 1838-46, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23853029
  • Hauser RA. PROUD stands tall: delayed-start studies in Parkinson's disease. Lancet Neurology. 12(8) : 728-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23726852
  • Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28(6) : 817-20, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23589371
  • Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery, and psychiatry. 84(11) : 1288-95, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23486993
  • Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet neurology. 12(4) : 346-56, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23485610
  • Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response? Movement disorders : official journal of the Movement Disorder Society. 28(3) : 341-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23390076
  • Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain : A Journal of Neurology. 136(2) : 433-43, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23378216
  • Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism & related disorders. 19(3) : 339-45, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23287001
  • Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. Journal of neural transmission (Vienna, Austria : 1996). 120(2) : 299-307, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22878514
  • Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 180-7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22845710
  • Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 50-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22537207
  • The Parkinson Study Group (including Hauser RA). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD) Mov Disord. 28(13) : 1823-31, 2013.
  • Hauser RA, Hewitt LA, Isaacson S. Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A). Journal of Parkinson's disease. : 57-65, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24326693
  • Elm JJ; The NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1 Mov Disord. 12(27) : 1513-1521, 2012.
  • Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clinical Neuropharmacology. 35(5) : 208-14, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22948497
  • Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clinical neuropharmacology. 35(4) : 174-81, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22801294
  • Morelli M, Blandini F, Simola N, Hauser RA. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinson's disease. 2012: 489853, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22754707
  • Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 22(3) : 225-30, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21410815
  • Hauser RA, Lyons KE, Pahwa R. The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. The International journal of neuroscience. 122(7) : 333-7, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22329569
  • Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & related disorders. 18(4) : 370-6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22316635
  • Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert review of neurotherapeutics. 12(2) : 133-40, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22288668
  • Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Head injury, α-synuclein Rep1, and Parkinson's disease. Annals of neurology. 71(1) : 40-8, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22275250
  • Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 79(2) : 163-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22744665
  • Hauser RA, Auinger P, Parkinson Study Group. Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease. Mov Disord. 5(26) : 813-8., 2011.
  • Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease. Int J Neurosci. 5(121) : 246-53, 2011.
  • Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; for the Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord. 8(26) : 1464-76, 2011.
  • Rascol, O., Fitzer-Attas, C.J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., …& Olanow, C. W. A double-blind, delayed-start trial of rasgiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet Neurology. 5(10) : 415-423, 2011.
  • Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; the Spheramine Investigational Group. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol. 6(10) : 509-519, 2011.
  • Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet neurology. 10(3) : 221-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21315654
  • Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci.. 8(121) : 767-74, 2011.
  • Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial Neurology. 8(77) : 759-66, 2011.
  • Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease Mov Disord. 12(26) : 2246-52, 2011.
  • Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 77(8) : 767-74, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21832216
  • Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipeline Int J Neurosci.. 2(121) : 53-62, 2011.
  • Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology. 6(24) : 721-30, 2010.
  • Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25(15) : 2542-9, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20669317
  • Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25(14) : 2326-32, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20669265
  • Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. Long-term efficacy of rasagiline in early Parkinson's disease. The International Journal of neuroscience. 120(6) : 404-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20504210
  • Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Movement Disorders : Official Journal of the Movement Disorder Society. 25(7) : 927-31, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20461810
  • Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25(7) : 858-66, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20461803
  • Hauser RA. Early pharmacologic treatment in Parkinson's disease. The American Journal of Managed Care. 16: S100-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20297870
  • Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Movement Disorders : Official Journal of the Movement Disorder Society. 25(9) : 1131-42, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20310033
  • Bronzova J, Sampaio C, Hauser RA, Lang AE, Rascol O, Theeuwes A, van de Witte SV, van Scharrenburg G. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25(6) : 730-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20198713
  • Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clinical Neuropharmacology. 33(1) : 5-10, 2010. http://www.ncbi.nlm.nih.gov/pubmed/19855267
  • Hauser RA. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism & Related Disorders. 15: S17-21, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20082983
  • Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24(4) : 541-50, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19058133
  • Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24(16) : 2328-36, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19908302
  • Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA. Sleep disorders in Parkinson's disease. Neuropsychiatric Disease and treatment. 5: 535-40, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19898667
  • Sethi KD, Hauser RA, Isaacson SH, McClain T. Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series. Cases Journal. 2: 7134, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19829918
  • Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Occupation and risk of parkinsonism: a multicenter case-control study. Archives of Neurology. 66(9) : 1106-13, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19752299
  • Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR, Chu Y, Mufson EJ, Kordower JH, Freeman TB. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America. 106(30) : 12483-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19620721
  • Seeberger LC, Hauser RA. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert Review of Neurotherapeutics. 9(7) : 929-40, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19589043
  • Connors JJ, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, Hadley MN, Wojak JC, Koroshetz WJ, Heros RC, Strother CM, Duckwiler GR, Durham JD, Tom-sick TO, Rosenwasser RH, McDougall CG, Haughton VM, Derdeyn CP, Wechsler LR, Hudgins PA, Alberts MJ, Raabe RD, Gomez CR, Cawley CM, Krol KL, Futrell N, Hauser RA, Frank JI. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Journal of vascular and interventional radiology : JVIR. 20(7 Suppl) : S292-301, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19560013
  • Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clinical neuropharmacology. 32(1) : 48-50, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19471184
  • Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, van de Witte SV. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. European neurology. 62(1) : 40-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19407454
  • Hauser RA. Levodopa: past, present, and future. European neurology. 62(1) : 1-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19407449
  • Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(7) : 979-83, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19230029
  • Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 2. European neurology. 61(4) : 206-15, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19176961
  • Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 1. European neurology. 61(4) : 193-205, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19176960
  • Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(4) : 564-73, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19086083
  • Isaacson SH, Hauser RA. Improving symptom control in early Parkinson's disease. Therapeutic advances in neurological disorders. 2(6) : 29-41, 2009. http://www.ncbi.nlm.nih.gov/pubmed/21180628
  • Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2194-201, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18932271
  • Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Movement disorders : official journal of the Movement Disorder Society. 23(16) : 2303-6, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19006193
  • Shimberg WR, Patel NB, Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for stiff-person syndrome: report of 2 patients. Clinical neuropharmacology. 31(5) : 301-2, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18836351
  • Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. Clinical rheumatology. 27(3) : 389-90, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17938990
  • Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Leurgans S. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Movement disorders : official journal of the Movement Disorder Society. 23(5) : 690-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18228568
  • Zesiewicz TA, Sullivan KL, Hoffmann M, Benes LM, Smith DA, Ward CL, Hauser RA. Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation. European neurology. 59(3-4) : 187-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18230878
  • Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature medicine. 14(5) : 504-6, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18391962
  • Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. European neurology. 60(2) : 57-66, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18480609
  • Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC. Caffeine and progression of Parkinson disease. Clinical neuropharmacology. 31(4) : 189-96, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18670242
  • Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2177-85, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18831530
  • Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacology. 53(7) : 791-800, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17936857
  • Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement disorders : official journal of the Movement Disorder Society. 22(16) : 2409-17, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17894339
  • Simonson W, Hauser RA, Schapira AH. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. The Annals of pharmacotherapy. 41(11) : 1842-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17878397
  • Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance (SSDI) in Parkinson's disease. Disability and rehabilitation. 29(24) : 1934-6, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17852221
  • Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and exacerbation of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(14) : 2132-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17663461
  • Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(2) : 279-82, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17149715
  • Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(1) : 139-41, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17089400
  • Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Parkinsonism & related disorders. 13(8) : 545, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17188922
  • Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy. 8(5) : 657-64, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17376020
  • Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. The neurologist. 13(3) : 126-32, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17495756
  • Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(11) : 1660-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17580330
  • Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Current neurology and neuroscience reports. 7(4) : 302-10, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17618536
  • Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 22(3) : 359-65, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17149725

Awards/Honors

  • America'a Top Doctors (Top 1%) (Castle Connolly - 2013)
  • Board Certification (American Society of Neuroimaging (MRI - Magnetic Resonance Imaging) - 2012)
  • Board Certification (American Board of Psychiatry & Neurology - 2012)
  • America'a Top Doctors (Top 1%) (Castle Connolly - 2012)
  • America's Top Doctors (Castle Connolly - 2011)
  • America's Top Doctors (Castle Connolly - 2010)
  • America's Top Doctors (Castle Connolly - 2009)
  • America's Top Doctors (Castle Connolly - 2008)
  • America's Top Doctors (Castle Connolly - 2008)
  • America's Top Doctors (Castle Connolly - 2007)
  • America's Top Doctors (Castle Connolly - 2006)
  • MIllion Dollar Researcher (University of South Florida - 2006)
  • America's Top Doctors (Castle Connolly - 2005)
  • Center of Excellence (National Parkinson Foundation - 2005)
  • America's Top Doctors (Castle Connolly - 2004)
  • America's Top Doctors (Castle Connolly - 2003)